Chromocell Therapeutics Moves HQ, Files Officer/Director Changes

TL;DR

Chromocell moved its HQ to Freehold, NJ and filed changes to its board and exec team.

AI Summary

Chromocell Therapeutics Corp. announced on March 13, 2024, a change in its principal executive office to 4400 Route 9 South, Suite 1000, Freehold, NJ 07728. This move from their previous North Brunswick, NJ address is effective immediately. The company also filed information regarding the departure of directors, election of directors, appointment of officers, and compensatory arrangements.

Why It Matters

A change in principal executive office can indicate operational shifts or strategic realignments within the company. The filings related to directors and officers suggest potential governance changes.

Risk Assessment

Risk Level: medium — Changes in executive and director positions, along with a principal office relocation, can signal underlying operational or strategic shifts that may carry inherent risks.

Key Players & Entities

• Chromocell Therapeutics Corp. (company) — Registrant
• March 13, 2024 (date) — Earliest event reported
• 4400 Route 9 South, Suite 1000, Freehold, NJ 07728 (location) — New principal executive office address
• North Brunswick, NJ (location) — Previous principal executive office address

FAQ

Key Financial Figures

• $0.0001 — h registered Common Stock, par value $0.0001 per share CHRO The NYSE American LL
• $10 million — grow revenue from an annualized rate of $10 million to $100 million in six quarters by acqu
• $100 million — om an annualized rate of $10 million to $100 million in six quarters by acquiring three comp
• $300 million — s career, he has helped raise more than $300 million via venture equity and debt, public equ

Filing Documents

• g084130_8k.htm (8-K) — 34KB
• g084130_ex99-1.htm (EX-99.1) — 9KB
• image_001.jpg (GRAPHIC) — 3KB
• 0001753926-24-000550.txt ( ) — 223KB
• chro-20240313.xsd (EX-101.SCH) — 3KB
• chro-20240313_lab.xml (EX-101.LAB) — 33KB
• chro-20240313_pre.xml (EX-101.PRE) — 22KB
• g084130_8k_htm.xml (XML) — 4KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The board of directors (the "Board") of Chromocell Therapeutics Corporation (the "Company") has appointed Francis Knuettel II as Chief Executive Officer of the Company, effective March 13, 2024. Mr. Knuettel will serve as the Company's Chief Executive Officer until a successor is duly elected and qualified, unless sooner removed. In addition to his role as Chief Executive Officer of the Company, Mr. Knuettel will continue to serve in his capacity as Chief Financial Officer, Treasurer and Secretary of the Company. Mr. Knuettel, 57, has served as the Company's Interim Chief Executive Officer since July 2023, and as the Company's Chief Financial Officer, Treasurer and Secretary since June 2022. Prior to that, from December 2020 to April 2022, he served as Chief Executive Officer and director of Unrivaled Brands, a California-based operator of cannabis assets in California and Oregon, where he helped grow revenue from an annualized rate of $10 million to $100 million in six quarters by acquiring three companies in the sector. He also served as Chief Financial Officer of ONE Cannabis Group from June 2019 to January 2021 and held various roles at MJardin Group, including Chief Strategy Officer, from August 2018 to January 2019. Prior to MJardin Group, Mr. Knuettel served as Chief Financial Officer of Aqua Metals in 2018 and held the same position at Marathon Patent Group from 2014 to 2018. During Mr. Knuettel's career, he has helped raise more than $300 million via venture equity and debt, public equity and debt offerings in the United States and Canada, convertible debt, PIPEs, bridge loans and other instruments. In addition, he has managed more than 15 mergers and acquisition transactions of companies as both buyer and seller and has handled large-scale licensing transactions with fortune 50 companies. Mr. Knue

01

Item 8.01 Other Events. On March 18, 2023, the Company issued a press release announcing the appointment of Mr. Knuettel as the Company's Chief Executive Officer, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in such exhibit shall not be deemed filed for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

01

Item 9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Chromocell Therapeutics Corporation, dated March 18, 2023. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 18, 2024 CHROMOCELL THERAPEUTICS CORPORATION By: /s/ Francis Knuettel II Name: Francis Knuettel II Title: Chief Executive Officer and Chief Financial Officer